✦ LIBER ✦

Response to clinical hyperthermia: Mirage or reality?

✍ Scribed by Stephen A. Sapareto

Publisher: Elsevier Science
Year: 1984
Tongue: English
Weight: 168 KB
Volume: 10
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(84)90404-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical hyperthermia: Mirage or reality

Clinical hyperthermia: Mirage or reality?

✍ Carlos A. Perez 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 402 KB

Transforming power of immunosuppression:

Transforming power of immunosuppression: Experimental mirage or clinical mirror to the future

✍ Gregory J. Gores 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB

Response to the letter to the editors by

Response to the letter to the editors by Ottaiano et al.: “Cetuximab-dependent ADCC in cancer: dream or reality?”

✍ Robert L. Ferris; Soldano Ferrone 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 114 KB

Studies on fractionated hyperthermia in

Studies on fractionated hyperthermia in experimental animal systems II. Response of murine tumors to two or more doses

✍ Muneyasu Urano; Laurie Cochran Rice; Vernon Montoya 📂 Article 📅 1982 🏛 Elsevier Science 🌐 English ⚖ 805 KB

An evaluation of predictive factors invo

An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer

✍ Reiki Nishimura; Kazuharu Nagao; Haruhiko Miyayama; Masakazu Matsuda; Ken-ichiro 📂 Article 📅 2002 🏛 Springer Japan 🌐 English ⚖ 696 KB

Clinical outcome after 4 years follow-up

Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART

✍ Emanuele Nicastri; Antonio Chiesi; Claudio Angeletti; Loredana Sarmati; Lucia Pa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract The duration of the clinical, virologic, and immunologic response to HAART, is not well defined. In this observational multi‐center study 2,143 patients were enrolled classified according to virologic suppression (<500 cp/ml) and immune recovery (>100 CD4+ cells/μl from baseline) at mon